Fennec Pharma

33 articles with Fennec Pharma

• Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences - Sep 09, 2021

  9/9/2021

  Fennec Pharmaceuticals Inc. announced that management will participate in three upcoming virtual investor conferences, including H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit taking place September 20-23, 2021, and the 2021 Cantor Virtual Global Healthcare Conference taking place September 27-30, 2021.

• Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update

  8/10/2021

  Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients, reported its financial results for the second quarter ended June 30, 2021 and provided a business update.

• Fennec Announces Results of Annual Meeting - June 29, 2021

  6/29/2021

  Fennec Pharmaceuticals Inc. announced that the nominees listed in the management proxy circular dated May 14, 2021 for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in Irvine, California and online on June 29, 2021.

• Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility - June 24, 2021

  6/24/2021

  Fennec Pharmaceuticals Inc. announced an amendment to its existing senior debt facility with the Life Sciences Group at Bridge Bank increasing the size of the facility from $18 million to $20 million.

• Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK™

  6/22/2021

  Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for filing the resubmission of its New Drug Application for PEDMARK™ for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to < 18 years of age with localized, non-metastatic, solid tumors.

• 

  Fennec Tries Again for FDA Approval of Chemotherapy-Induced Hearing Loss Drug

  5/28/2021

  Fennec is looking for a second chance to approve PEDMARK, its pediatric chemotherapy-induced hearing loss prevention drug, as it resubmits its NDA for the agent to the U.S. FDA.

• Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for PEDMARK™

  5/28/2021

  If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children

• Fennec Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update

  5/13/2021

  Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARKTM for the prevention of platinum-induced ototoxicity in pediatric patients, reported its financial results for the first quarter ended March 31, 2021 and provided a business update.

• Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update

  3/30/2021

  Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug Application (NDA) Resubmission for PEDMARK™

• Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update

  11/16/2020

  ~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARK™  ~ ~ No Clinical Safety or Efficacy Issues Identified ; No Additional Studies Required for PEDMARK™  ~ ~ The Company Has Approximately $33 Million in Cash and No Outstanding Debt ~

• Fennec Announces Issuance of U.S. Patent for PEDMARK™

  9/21/2020

  Fennec Pharmaceuticals Inc. announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,792,363 entitled “Anhydrous Sodium Thiosulfate and Formulations Thereof.”

• Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences - Aug 12, 2020

  8/12/2020

  Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, announced that Rosty Raykov, Chief Executive Officer of Fennec will present at the following upcoming investor conferences.

• Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors

  8/11/2020

  FDA Pre-Approval Inspection has Identified Deficiencies with the Facility of the Drug Product Manufacturer, which Require Resolution Prior to PEDMARK Approval

• 

  FDA Action Alert: Fennec, Gilead/Kite, Deciphera and Jazz/PharmaMar

  8/10/2020

  Although August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar for PDUFA dates, this week’s dates were almost all approved ahead of schedule. Here’s a look.

• Fennec Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update

  8/5/2020

  Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARKTM for the prevention of platinum-induced ototoxicity in pediatric patients, reported its financial results for the second quarter ended June 30, 2020 and provided a business update.

• Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility

  6/26/2020

  Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients, announced an amendment to its existing senior debt facility with the Life Sciences Group at Bridge Bank increasing the size of the facility from $12.5 million to $18 million.

• Fennec Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Business Update

  5/14/2020

  Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARKTM for the prevention of platinum-induced ototoxicity in pediatric patients, reported its financial results for the first quarter ended March 31, 2020 and provided a business update.

• Fennec Announces Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

  5/8/2020

  Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced that in connection with its previously completed underwritten offering on May 4, 2020 of $30,000,000 at a price of $6.25 per share, the option g

• Fennec Announces Closing of Public Offering - May 05, 2020

  5/5/2020

  Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARKTM for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, announced the closing of its previously announced underwritten public offering of 4,800,000 common shares at a public offering price of $6.25 per share.

• Fennec Announces Pricing of Public Offering - April 30, 2020

  4/30/2020

  Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARKTM for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, announced the pricing of its underwritten public offering of 4,800,000 common shares at a public offering price of $6.25 per share.